13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001822947
Total reported value
$113.1M
$113.1M
26 檔
40.7%
At the close of Q1 2026, Ally Bridge Group disclosed equity holdings valued at approximately $113.1M, spread across 26 reported holdings.
In Q1 2026, Ally Bridge Group displayed an active expansion posture, initiating 12 new positions and adding to 7 existing holdings, outstripping position reductions.
In terms of portfolio concentration, the top 5 core holdings (including SLNOEUR, PRAX, NERV) accounted for 40.7% of total reported equity market value during Q1 2026.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 10.82% | -10.82% | EXIT | |
| 2 | PRAX | Praxis Precision Medicines I | Stock-Other | 8.54% | -8.54% | EXIT | |
| 3 | NERV | Minerva Neurosciences Inc | Stock-Other | 8.06% | +2.62% | — | |
| 4 | OVID | Ovid Therapeutics Inc | Stock-Other | 5.05% | -3.56% | +57.90% | |
| 5 | CMPS | Compass Pathways PLC | Stock-Other | 4.67% | -4.67% | EXIT | |
| 6 | TARS | Tarsus Pharmaceuticals Inc | Stock-Other | 4.58% | -4.58% | EXIT | |
| 7 | SLDB | Solid Biosciences Inc | Stock-Other | 4.46% | -2.20% | +85.43% | |
| 8 | CMPX | Compass Therapeutics Inc | Stock-Other | 4.27% | -4.27% | EXIT | |
| 9 | PMN | Promis Neurosciences Inc | Stock-Other | 4.25% | +2.97% | +66.13% | |
| 10 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 4.10% | -1.11% | -63.82% | |
| 11 | QURE | uniQure N.V. | Stock-Other | 3.96% | -3.96% | EXIT | |
| 12 | EPRX | Eupraxia Pharmaceuticals Inc | Stock-Other | 3.86% | -2.39% | +65.97% | |
| 13 | CTMX | Cytomx Therapeutics Inc | Stock-Other | 3.42% | -0.85% | — | |
| 14 | IVA | Inventiva SA - Adr | Stock-Other | 3.34% | -1.22% | -50.31% | |
| 15 | CATX | Perspective Therapeutics Inc | Stock-Other | 3.12% | -0.88% | — | |
| 16 | ABVX | Abivax Sa-adr | Stock-Other | 3.03% | +11.70% | -51.84% | |
| 17 | ALMS | Alumis Inc | Stock-Other | 2.97% | -1.07% | — | |
| 18 | URGN | UroGen Pharma Ltd. | Stock-Other | 2.94% | -0.69% | — | |
| 19 | CAPR | Capricor Therapeutics Inc | Stock-Other | 2.80% | -2.80% | EXIT | |
| 20 | MAZE | Maze Therapeutics Inc | Stock-Other | 2.41% | -2.41% | EXIT | |
| 21 | WHWK | Whitehawk Therapeutics Inc | Stock-Other | 2.28% | +1.03% | — | |
| 22 | IKT | Inhibikase Therapeutics Inc | Stock-Other | 1.80% | -1.80% | EXIT | |
| 23 | REPL | Replimune Group Inc | Stock-Other | 1.53% | -1.53% | EXIT | |
| 24 | ANTX | An2 Therapeutics Inc | Stock-Other | 1.45% | +0.80% | — | |
| 25 | RLMD | Relmada Therapeutics Inc | Stock-Other | 1.18% | -1.18% | EXIT | |
| 26 | KPTI | Karyopharm Therapeutics Inc | Stock-Other | 1.12% | -1.12% | EXIT |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | SLNOEUR | Soleno Therapeutics Inc | +2.7% | +138.05% | Add |
| 2 | PMN | Promis Neurosciences Inc | +2.5% | +66.13% | Add |
| 3 | PRAX | Praxis Precision Medicines I | +2.4% | +65.02% | Add |
| 4 | SLDB | Solid Biosciences Inc | +2% | +85.43% | Add |
| 5 | OVID | Ovid Therapeutics Inc | +2% | +57.90% | Add |
| 6 | NERV | Minerva Neurosciences Inc | +1.1% | — | Unchanged |
| 7 | EPRX | Eupraxia Pharmaceuticals Inc | +0.7% | +65.97% | Add |
| 8 | WHWK | Whitehawk Therapeutics Inc | +0.2% | — | Unchanged |
| 9 | QURE | uniQure N.V. | -1% | +50.00% | Add |
| 10 | CMPS | Compass Pathways PLC | -3.2% | -5.00% | Trim |
| 11 | IVA | Inventiva SA - Adr | -3.9% | -50.31% | Trim |
| 12 | ABVX | Abivax Sa-adr | -6.8% | -51.84% | Trim |
| 13 | EWTX | Edgewise Therapeutics Inc | -7.4% | -63.82% | Trim |
| 14 | REPL | Replimune Group Inc | -10.6% | -79.42% | Trim |
| 15 | ATAI | AtaiBeckley Inc. | — | EXIT | Sold out |
| 16 | TARS | Tarsus Pharmaceuticals Inc | — | NEW | New buy |
| 17 | CMPX | Compass Therapeutics Inc | — | NEW | New buy |
| 18 | TSHA | Taysha Gene Therapies Inc | — | EXIT | Sold out |
| 19 | CTMX | Cytomx Therapeutics Inc | — | NEW | New buy |
| 20 | CATX | Perspective Therapeutics Inc | — | NEW | New buy |
| 21 | ALMS | Alumis Inc | — | NEW | New buy |
| 22 | URGN | UroGen Pharma Ltd. | — | NEW | New buy |
| 23 | CAPR | Capricor Therapeutics Inc | — | NEW | New buy |
| 24 | MAZE | Maze Therapeutics Inc | — | NEW | New buy |
| 25 | IKT | Inhibikase Therapeutics Inc | — | NEW | New buy |
| 26 | ANTX | An2 Therapeutics Inc | — | NEW | New buy |
| 27 | RLMD | Relmada Therapeutics Inc | — | NEW | New buy |
| 28 | KPTI | Karyopharm Therapeutics Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Ally Bridge Group reported a total U.S. public equity portfolio value of $113.1M across 26 disclosed positions in Q1 2026.
During Q1 2026, Ally Bridge Group's top holdings by market value included SLNOEUR (10.8%)、PRAX (8.5%)、NERV (8.1%). The largest single position, SLNOEUR, represented 10.8% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
TARS
市值: $5.7M
Top Position Liquidated / Trimmed
ATAI
前期市值: $7.0M
In Q1 2026, Ally Bridge Group made 26 total portfolio adjustments, initiating 12 new buys, adding to 7 positions, trimming 5 holdings, and fully liquidating 2 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.